Skip to main content

Advertisement

SpringerLink
Log in

Tight control is important in patients with rheumatoid arthritis treated with an anti-tumor necrosis factor biological agent: prospective study of 91 cases who used a biological agent for more than 1 year

  • Original Article
  • Published:
Modern Rheumatology

Abstract

The purpose of this study is to identify the factors that require arthroplasty due to the progression of joint destruction, even when an anti-tumor necrosis factor (TNF) biological agent is used for rheumatoid arthritis (RA). Among 91 cases that used the anti-TNF biological agent for more than 1 year, two groups of 21 cases that resulted in arthroplasty (surgery group) and 70 cases that did not result in arthroplasty (non-surgery group) were compared and examined. When the anti-TNF biological agent was first administered, disease activity and internal use of glucocorticoid (PSL) were not different in these two groups. The average DAS28-CRP(4) (disease activity score including a 28-joint count/C-reactive protein) (p < 0.001) and the amount of internal use of PSL (p < 0.05) were significantly decreased in the non-surgery group compared with the surgery group at the final survey. To inhibit the need for joint surgery in patients using the anti-TNF biological agent, it is important to maintain tight control over RA activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861–74.

    Article  PubMed  CAS  Google Scholar 

  2. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004;363:675–81.

    Article  PubMed  CAS  Google Scholar 

  3. Landewe R, Van der Heijde D, Klareskog L, Van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate. Arthritis Rheum. 2006;54:3119–25.

    Article  PubMed  CAS  Google Scholar 

  4. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group; sustained improvement over two years in physical function. Structual damage and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50:1051–65.

    Article  PubMed  CAS  Google Scholar 

  5. Smolen JS, van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006;54:702–10.

    Article  PubMed  CAS  Google Scholar 

  6. van Riel PL. Provisional guidelines for measuring disease activity in RA clinical trials. Br J Rheumatol. 1992;31:793–4.

    Article  PubMed  Google Scholar 

  7. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–61.

    Article  PubMed  CAS  Google Scholar 

  8. Weaver AL. Efficacy and safety of the anti-TNF biological agents. Mod Rheumatol. 2004;14:101–12.

    Article  PubMed  CAS  Google Scholar 

  9. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis, 2002 update. Arthritis Rheum. 2002;46:328–46.

    Article  Google Scholar 

  10. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34–45.

    Google Scholar 

  11. Breedvelt FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.

    Article  Google Scholar 

  12. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594–602.

    Article  PubMed  CAS  Google Scholar 

  13. Keystone EC, Kavanaugh AF, Sharp JT, Tnannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400–11.

    Article  PubMed  CAS  Google Scholar 

  14. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombination tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–9.

    Article  PubMed  CAS  Google Scholar 

  15. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27:261–3.

    PubMed  Google Scholar 

  16. Larsen A, Dale K, EEK M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn. 1977;18:481–91.

    CAS  Google Scholar 

  17. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.

    Article  PubMed  CAS  Google Scholar 

  18. van der Heijde DM, van Riel PL, van Leeuwen MA, van’t Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol. 1992;31:519–22.

    Article  PubMed  Google Scholar 

  19. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. comparison of disease activity score (DAS) 28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007;66:407–9.

    Article  PubMed  CAS  Google Scholar 

  20. Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007;17:28–32.

    Article  PubMed  CAS  Google Scholar 

  21. Sano H, Arai K, Murai T, Fujisawa J, Endo N. Short-term results of etanercept in rheumatoid arthritis. Arch Niigata Soc Orthop Surg. 2007;23:51–4 (in Japanese).

    Google Scholar 

  22. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement. Arthritis Rheum. 2005;52:1020–30.

    Article  PubMed  CAS  Google Scholar 

  23. Abe A, Ishikawa H, Murasawa A, Nakazono K. Disease activity and the course of elbow joint deterioration over 10 years in the patients with early rheumatoid arthritis. Clin Rheumatol. 2007;27:867–72.

    Article  PubMed  Google Scholar 

  24. Tanaka E, Mannalithara A, Inoue E, Hara M, Tomatsu T, Kamatani N, et al. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. Ann Rheum Dis. 2008;67:1153–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, 1-754 Asahimachi, Chuoku, Niigata, Niigata, 951-8520, Japan

    Hiroshige Sano, Katsumitsu Arai, Takehiro Murai, Junichi Fujisawa, Naoki Kondo, Takahiro Netsu & Naoto Endo

  2. Department of Rheumatology, Nagaoka Red Cross Hospital, 2-297-1 Sensyu, Nagaoka, Niigata, 940-2085, Japan

    Tadamasa Hanyu

  3. Department of Internal Medicine, Nagaoka Red Cross Hospital, 2-297-1 Sensyu, Nagaoka, Niigata, 940-2085, Japan

    Takako Saeki & Tomoyuki Ito

Authors
  1. Hiroshige Sano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katsumitsu Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takehiro Murai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junichi Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naoki Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takahiro Netsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tadamasa Hanyu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takako Saeki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomoyuki Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Naoto Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshige Sano.

About this article

Cite this article

Sano, H., Arai, K., Murai, T. et al. Tight control is important in patients with rheumatoid arthritis treated with an anti-tumor necrosis factor biological agent: prospective study of 91 cases who used a biological agent for more than 1 year. Mod Rheumatol 19, 390–394 (2009). https://doi.org/10.1007/s10165-009-0177-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-009-0177-x

Keywords

Search

Navigation